Literature DB >> 6116956

Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immunoregulation.

G Janossy, G Panayi, O Duke, M Bofill, L W Poulter, G Goldstein.   

Abstract

In rheumatoid arthritis the synovial membrane has many of the characteristics of a hyperactive, immunologically-stimulated lymphoid organ. The basis of this hyperactivity is poorly understood. Highly specific antisera to human Ia-like (HLA-DR) antigens and monoclonal antibodies (OKT series) to various T-lymphocyte subsets were used to analyse both the normal and the rheumatoid synovium and to compare it with normal lymph nodes. In rheumatoid arthritis the synovium acquires an infiltrate with microanatomical similarities to the paracortical area of the lymph node. Large, very strongly HLA-DR-positive macrophage-like interdigitating cells form close contacts with the OKT4+ (inducer-type) T-cells, while the OKT8+ population (T-cells of suppressor-cytotoxic type) between the macrophage-OKT4+ cell clusters is scanty (T4/T8 ratio = 9:1). By contrast, in the lymph node there are more OKT8 T-cells interspersed between the HLA-DR+ interdigitating cells and OKT4+ cells (T4/T8 ratio = 2:1). The large interdigitating cells and the OKT4+ T-cell population may be mutually stimulatory. In the absence of efficient suppression this stimulation may lead to activation of B-lymphocytes and oligoclonal or polyclonal immunoglobulin synthesis, as is found in the synovial membrane in rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6116956     DOI: 10.1016/s0140-6736(81)91107-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  197 in total

Review 1.  Synovial biopsy in arthritis research: five years of concerted European collaboration.

Authors:  B Bresnihan; P P Tak; P Emery; L Klareskog; F Breedveld
Journal:  Ann Rheum Dis       Date:  2000-07       Impact factor: 19.103

2.  Evidence for the presence of activated CD4 T cells with naive phenotype in the peripheral blood of patients with rheumatoid arthritis.

Authors:  D Maurer; T Felzmann; W Holter; P Petera; J Smolen; W Knapp
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

3.  Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion.

Authors:  M J Leandro; J C W Edwards; G Cambridge
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

4.  Two-dimensional electrophoresis of synovial tissue, synovial fluid and serum in patients with rheumatoid arthritis and related diseases.

Authors:  P Fritz; N Arold; A Mischlinski; H Wisser; B Oeffinger; V Neuhoff; W Laschner; G Koenig
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

5.  Heterogeneity of T cell receptor idiotypes in rheumatoid arthritis.

Authors:  F M Brennan; S Allard; M Londei; C Savill; A Boylston; S Carrel; R N Maini; M Feldmann
Journal:  Clin Exp Immunol       Date:  1988-09       Impact factor: 4.330

6.  Morphometric comparison of synovium from patients with osteoarthritis and rheumatoid arthritis.

Authors:  T D Kennedy; C Plater-Zyberk; T A Partridge; D F Woodrow; R N Maini
Journal:  J Clin Pathol       Date:  1988-08       Impact factor: 3.411

7.  Rationale for thymopentin as therapeutic agent in rheumatoid arthritis.

Authors:  P Franchimont; K Bolla
Journal:  Surv Immunol Res       Date:  1985

8.  Hyaluronic acid production in vitro by synovial lining cells from normal and rheumatoid joints.

Authors:  I M Dahl; G Husby
Journal:  Ann Rheum Dis       Date:  1985-10       Impact factor: 19.103

9.  Expression of CD5 and CD72 on T and B cell subsets in rheumatoid arthritis and Sjögren's syndrome.

Authors:  C Jamin; A Lamour; Y L Pennec; M Hirn; P Le Goff; P Youinou
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

10.  Mechanisms of depressed delayed-type hypersensitivity in rheumatoid arthritis: the role of protein energy malnutrition.

Authors:  P Emery; G Panayi; D Symmons; G Brown
Journal:  Ann Rheum Dis       Date:  1984-06       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.